|
1
|
Dalton WS and Friend SH: Cancer biomarkers
- an invitation to the table. Science. 312:1165–1168. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Streppel MM, Vincent A, Mukherjee R,
Campbell NR, Chen SH, Konstantopoulos K, Goggins MG, Van Seuningen
I, Maitra A and Montgomery EA: Mucin 16 (cancer antigen 125)
expression in human tissues and cell lines and correlation with
clinical outcome in adenocarcinomas of the pancreas, esophagus,
stomach, and colon. Hum Pathol. 43:1755–1763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bafna S, Kaur S and Batra SK:
Membrane-bound mucins: The mechanistic basis for alterations in the
growth and survival of cancer cells. Oncogene. 29:2893–2904. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bocheva Y, Bochev P and Ivanov S: Ca-125
in diagnosis and monitoring of patients with ovarian cancer. Akush
Ginekol (Sofiia). 54:11–17. 2015.In Bulgarian.
|
|
5
|
Gąsiorowska E, Michalak M, Warchoł W,
Lemańska A, Jasiński P, Spaczyński M and Nowak-Markwitz E: Clinical
application of HE4 and CA125 in ovarian cancer type I and type II
detection and differential diagnosis. Ginekol Pol. 86:88–93. 2015.
View Article : Google Scholar
|
|
6
|
Gadducci A, Menichetti A, Guiggi I,
Notarnicola M and Cosio S: Correlation between CA125 levels after
sixth cycle of chemotherapy and clinical outcome in advanced
ovarian carcinoma. Anticancer Res. 35:1099–1104. 2015.PubMed/NCBI
|
|
7
|
Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J,
Cen P, Xu J, Liu C, Long J, et al: A preoperative serum signature
of CEA+/CA125+/CA19-9 ≥ 1000 U/ml indicates
poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer.
136:2216–2227. 2015. View Article : Google Scholar
|
|
8
|
Chen Y, Gao SG, Chen JM, Wang GP, Wang ZF,
Zhou B, Jin CH, Yang YT and Feng XS: Serum CA242, CA199, CA125,
CEA, and TSGF are biomarkers for the efficacy and prognosis of
cryo-ablation in pancreatic cancer patients. Cell Biochem Biophys.
Dec 9–2014.Epub ahead of print.
|
|
9
|
Okada K, Kawai M, Tani M, Hirono S,
Miyazawa M, Shimizu A, Kitahata Y and Yamaue H: Predicting factors
for unresectability in patients with pancreatic ductal
adenocarcinoma. J Hepatobiliary Pancreat Sci. 21:648–653. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bast RC Jr, Badgwell D, Lu Z, Marquez R,
Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, et al:
New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 15(Suppl
3): 274–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bressan A, Bozzo F, Maggi CA and Binaschi
M: OC125, M11 and OV197 epitopes are not uniformly distributed in
the tandem-repeat region of CA125 and require the entire SEA
domain. Dis Markers. 34:257–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Felder M, Kapur A, Gonzalez-Bosquet J,
Horibata S, Heintz J, Albrecht R, Fass L, Kaur J, Hu K, Shojaei H,
et al: MUC16 (CA125): Tumor biomarker to cancer therapy, a work in
progress. Mol Cancer. 13:1292014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Govindarajan B and Gipson IK:
Membrane-tethered mucins have multiple functions on the ocular
surface. Exp Eye Res. 90:655–663. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tyler C, Kapur A, Felder M, Belisle JA,
Trautman C, Gubbels JA, Connor JP and Patankar MS: The mucin MUC16
(CA125) binds to NK cells and monocytes from peripheral blood of
women with healthy pregnancy and preeclampsia. Am J Reprod Immunol.
68:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rachagani S, Torres MP, Kumar S, Haridas
D, Baine M, Macha MA, Kaur S, Ponnusamy MP, Dey P, Seshacharyulu P,
et al: Mucin (Muc) expression during pancreatic cancer progression
in spontaneous mouse model: Potential implications for diagnosis
and therapy. J Hematol Oncol. 5:682012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gipson IK and Argüeso P: Role of mucins in
the function of the corneal and conjunctival epithelia. Int Rev
Cytol. 231:1–49. 2003. View Article : Google Scholar
|
|
17
|
Haridas D, Chakraborty S, Ponnusamy MP,
Lakshmanan I, Rachagani S, Cruz E, Kumar S, Das S, Lele SM,
Anderson JM, et al: Pathobiological implications of MUC16
expression in pancreatic cancer. PLoS One. 6:e268392011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lakshmanan I, Ponnusamy MP, Das S,
Chakraborty S, Haridas D, Mukhopadhyay P, Lele SM and Batra SK:
MUC16 induced rapid G2/M transition via interactions with JAK2 for
increased proliferation and anti-apoptosis in breast cancer cells.
Oncogene. 31:805–817. 2012. View Article : Google Scholar :
|
|
19
|
Cedrés S, Nuñez I, Longo M, Martinez P,
Checa E, Torrejón D and Felip E: Serum tumor markers CEA,
CYFRA21-1, and CA-125 are associated with worse prognosis in
advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer.
12:172–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Higashi M, Yamada N, Yokoyama S, Kitamoto
S, Tabata K, Koriyama C, Batra SK and Yonezawa S: Pathobiological
implications of MUC16/CA125 expression in intrahepatic
cholangiocarcinoma-mass forming type. Pathobiology. 79:101–106.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Togami S, Nomoto M, Higashi M, Goto M,
Yonezawa S, Tsuji T, Batra SK and Douchi T: Expression of mucin
antigens (MUC1 and MUC16) as a prognostic factor for mucinous
adenocarcinoma of the uterine cervix. J Obstet Gynaecol Res.
36:588–597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Argüeso P, Guzman-Aranguez A, Mantelli F,
Cao Z, Ricciuto J and Panjwani N: Association of cell surface
mucins with galectin-3 contributes to the ocular surface epithelial
barrier. J Biol Chem. 284:23037–23045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen SH, Hung WC, Wang P, Paul C and
Konstantopoulos K: Mesothelin binding to CA125/MUC16 promotes
pancreatic cancer cell motility and invasion via MMP-7 activation.
Sci Rep. 3:18702013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giannakouros P, Comamala M, Matte I,
Rancourt C and Piché A: MUC16 mucin (CA125) regulates the formation
of multicellular aggregates by altering β-catenin signaling. Am J
Cancer Res. 5:219–230. 2015.
|
|
25
|
Ricardo S, Marcos-Silva L, Pereira D,
Pinto R, Almeida R, Söderberg O, Mandel U, Clausen H, Felix A,
Lunet N, et al: Detection of glyco-mucin profiles improves
specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
Mol Oncol. 9:503–512. 2015. View Article : Google Scholar
|
|
26
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim DH, Yun HY, Ryu DH, Han HS, Han JH,
Yoon SM and Youn SJ: Preoperative CA 125 is significant indicator
of curative resection in gastric cancer patients. World J
Gastroenterol. 21:1216–1221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paulson AS, Tran Cao HS, Tempero MA and
Lowy AM: Therapeutic advances in pancreatic cancer.
Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimada H, Noie T, Ohashi M, Oba K and
Takahashi Y: Clinical significance of serum tumor markers for
gastric cancer: A systematic review of literature by the Task Force
of the Japanese Gastric Cancer Association. Gastric Cancer.
17:26–33. 2014. View Article : Google Scholar
|
|
31
|
Li Y, Li DJ, Chen J, Liu W, Li JW, Jiang
P, Zhao X, Guo F, Li XW and Wang SG: Application of Joint Detection
of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of
Cholangiocarcinoma. Asian Pac J Cancer Prev. 16:3451–3455. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ballehaninna UK and Chamberlain RS: The
clinical utility of serum CA 19-9 in the diagnosis, prognosis and
management of pancreatic adenocarcinoma: An evidence based
appraisal. J Gastrointest Oncol. 3:105–119. 2012.PubMed/NCBI
|
|
33
|
Cwik G, Wallner G, Skoczylas T, Ciechanski
A and Zinkiewicz K: Cancer antigens 19-9 and 125 in the
differential diagnosis of pancreatic mass lesions. Arch Surg.
141:968–973; discussion 974. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
O'Brien DP, Sandanayake NS, Jenkinson C,
Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss
O, Gunu R, Dawnay A, et al: Serum CA19-9 is significantly
upregulated up to 2 years before diagnosis with pancreatic cancer:
Implications for early disease detection. Clin Cancer Res.
21:622–631. 2015. View Article : Google Scholar
|
|
35
|
Steinberg W: The clinical utility of the
CA 19-9 tumor-associated antigen. Am J Gastroenterol. 85:350–355.
1990.PubMed/NCBI
|
|
36
|
Chan A, Prassas I, Dimitromanolakis A,
Brand RE, Serra S, Diamandis EP and Blasutig IM: Validation of
biomarkers that complement CA19.9 in detecting early pancreatic
cancer. Clin Cancer Res. 20:5787–5795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Menczer J, Ben-Shem E, Golan A and Levy T:
The significance of normal pretreatment levels of CA125 (<35
U/mL) in epithelial ovarian carcinoma. Rambam Maimonides Med J.
6:e00052015. View Article : Google Scholar :
|
|
38
|
Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu
C, Xu J, Ni Q and Yu X: CA125 is superior to CA19-9 in predicting
the resectability of pancreatic cancer. J Gastrointest Surg.
17:2092–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou P, Qu H, Shi H, Sun G and He Q:
Predictive value of CA125 in peritoneal metastasis and prognosis of
patients with gastric carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi.
17:1027–1030. 2014.In Chinese. PubMed/NCBI
|
|
40
|
Hartwig W, Werner J, Jäger D, Debus J and
Büchler MW: Improvement of surgical results for pancreatic cancer.
Lancet Oncol. 14:e476–e485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
|
42
|
Simeone DM and Pandol SJ: The pancreas:
Biology, diseases, and therapy. Gastroenterology. 144:1163–1165.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu F, Du F and Chen X: Multiple tumor
marker protein chip detection system in diagnosis of pancreatic
cancer. World J Surg Oncol. 12:3332014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rao TD, Tian H, Ma X, Yan X, Thapi S,
Schultz N, Rosales N, Monette S, Wang A, Hyman DM, et al:
Expression of the carboxy-terminal portion of MUC16/CA125 induces
transformation and tumor invasion. PLoS One. 10:e01266332015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Das S, Rachagani S, Torres-Gonzalez MP,
Lakshmanan I, Majhi PD, Smith LM, Wagner KU and Batra SK:
Carboxyl-terminal domain of MUC16 imparts tumorigenic and
metastatic functions through nuclear translocation of JAK2 to
pancreatic cancer cells. Oncotarget. 6:5772–5787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hoshino M, Kawashima H, Ogose A, Kudo N,
Ariizumi T, Hotta T, Umezu H, Hatano H, Morita T, Nishio J, et al:
Serum CA 125 expression as a tumor marker for diagnosis and
monitoring the clinical course of epithelioid sarcoma. J Cancer Res
Clin Oncol. 136:457–464. 2010. View Article : Google Scholar
|
|
47
|
Xu HX, Chen T, Wang WQ, Wu CT, Liu C, Long
J, Xu J, Zhang YJ, Chen RH, Liu L, et al: Metabolic tumour burden
assessed by 18F-FDG PET/CT associated with serum CA19-9
predicts pancreatic cancer outcome after resection. Eur J Nucl Med
Mol Imaging. 41:1093–1102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Luo G, Liu Z, Guo M, Jin K, Xiao Z, Liu L,
Xu J, Zhang B, Liu C, Huang D, et al: (18)F-FDG PET/CT can be used
to detect nonfunctioning pancreatic neuroendocrine tumors. Int J
Oncol. 45:1531–1536. 2014.PubMed/NCBI
|
|
49
|
Shi S, Ji S, Qin Y, Xu J, Zhang B, Xu W,
Liu J, Long J, Liu C, Liu L, et al: Metabolic tumor burden is
associated with major oncogenomic alterations and serum tumor
markers in patients with resected pancreatic cancer. Cancer Lett.
360:227–233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xiang J, Liu L, Wang W, Xu H, Wu C, Xu J,
Liu C, Long J, Ni Q and Yu X: Metabolic tumor burden: A new
promising way to reach precise personalized therapy in PDAC. Cancer
Lett. 359:165–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mercadal L: Tumour markers in chronic
kidney disease. Nephrol Ther. 11:122–124. 2015.In French.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ng WW, Tong KJ, Tam TN and Lee SD:
Clinical values of CA19-9, CA125 and CEA in malignant obstructive
jaundice. Zhonghua Yi Xue Za Zhi (Taipei). 55:438–446. 1995.
|
|
53
|
Chen T, Zhang MG, Xu HX, Wang WQ, Liu L
and Yu XJ: Preoperative serum CA125 levels predict the prognosis in
hyperbilirubinemia patients with resectable pancreatic ductal
adenocarcinoma. Medicine (Baltimore). 94:e7512015.
|
|
54
|
Lai H, Jin Q, Lin Y, Mo X, Li B, He K and
Chen J: Combined use of lysyl oxidase, carcino-embryonic antigen,
and carbohydrate antigens improves the sensitivity of biomarkers in
predicting lymph node metastasis and peritoneal metastasis in
gastric cancer. Tumour Biol. 35:10547–10554. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chanvorachote P, Luanpitpong S, Chunhacha
P, Promden W and Sriuranpong V: Expression of CA125 and cisplatin
susceptibility of pleural effusion-derived human lung cancer cells
from a Thai patient. Oncol Lett. 4:252–256. 2012.PubMed/NCBI
|
|
56
|
Kawabe T, Hirano M, Mohri M, Sugimoto T,
Nagata Y, Hisada M, Muto H, Unuma T, Momose T, Naka H, et al: CA125
in patients with pleural effusion - in comparison with ascites
patients. Rinsho Byori. 35:905–909. 1987.In Japanese. PubMed/NCBI
|
|
57
|
Duraker N, Hot S, Polat Y, Höbek A,
Gençler N and Urhan N: CEA, CA 19-9, and CA 125 in the differential
diagnosis of benign and malignant pancreatic diseases with or
without jaundice. J Surg Oncol. 95:142–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Parsons CM, Sutcliffe JL and Bold RJ:
Preoperative evaluation of pancreatic adenocarcinoma. J
Hepatobiliary Pancreat Surg. 15:429–435. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Callery MP, Chang KJ, Fishman EK,
Talamonti MS, William Traverso L and Linehan DC: Pretreatment
assessment of resectable and borderline resectable pancreatic
cancer: expert consensus statement. Ann Surg Oncol. 16:1727–1733.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Valls C, Andia E, Sanchez A, Fabregat J,
Pozuelo O, Quintero JC, Serrano T, Garcia-Borobia F and Jorba R:
Dual-phase helical CT of pancreatic adenocarcinoma: assessment of
resectability before surgery. AJR Am J Roentgenol. 178:821–826.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Maithel SK, Maloney S, Winston C, Gonen M,
D'Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF and Allen PJ:
Preoperative CA 19-9 and the yield of staging laparoscopy in
patients with radiographically resectable pancreatic
adenocarcinoma. Ann Surg Oncol. 15:3512–3520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Addeo P, Rosso E, Fuchshuber P,
Oussoultzoglou E, De Blasi V, Simone G, Belletier C, Dufour P and
Bachellier P: Resection of borderline resectable and locally
advanced pancreatic adenocarcinomas after neoadjuvant chemotherapy.
Oncology. 89:37–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Naik R and Barton DP: Neoadjuvant
chemotherapy or primary surgery in advanced ovarian cancer. N Engl
J Med. 363:2370–2371; author reply 2372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pross M, Wellner UF, Honselmann KC, Jung
C, Deichmann S, Keck T and Bausch D: Neoadjuvant therapy in
pancreatic cancer: Review article. JOP. 16:110–114. 2015.PubMed/NCBI
|
|
65
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Petrelli F, Coinu A, Borgonovo K, Cabiddu
M, Ghilardi M, Lonati V, Aitini E and Barni S; Gruppo Italiano per
lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD).
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or
unresectable pancreatic cancer: A meta-analytical review of
published studies. Pancreas. 44:515–521. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Shimizu A, Hirono S, Tani M, Kawai M,
Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S, et
al: Coexpression of MUC16 and mesothelin is related to the invasion
process in pancreatic ductal adenocarcinoma. Cancer Sci.
103:739–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Pelissier A, Bonneau C, Chéreau E, de La
Motte Rouge T, Fourchotte V, Daraï E and Rouzier R: CA125 kinetic
parameters predict optimal cytoreduction in patients with advanced
epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Gynecol Oncol. 135:542–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mou W, Liu Z, Luo Y, Zou M, Ren C, Zhang
C, Wen X, Wang Y and Tian Y: Development and cross-validation of
prognostic models to assess the treatment effect of
cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients.
Med Oncol. 31:592014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hwang GI, Yoo CH, Sohn BH, Shin JH, Park
YL, Kim HD, Kim YS, Han WK and Pae WK: Predictive value of
preoperative serum CEA, CA19-9 and CA125 levels for peritoneal
metastasis in patients with gastric carcinoma. Cancer Res Treat.
36:178–181. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Pignata S, Cannella L, Leopardo D, Bruni
GS, Facchini G and Pisano C: Follow-up with CA125 after primary
therapy of advanced ovarian cancer: in favor of continuing to
prescribe CA125 during follow-up. Ann Oncol. 22(Suppl 8):
viii40–viii44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Myriokefalitaki E, Vorgias G, Vlahos G and
Rodolakis A: Prognostic value of preoperative Ca125 and Tag72 serum
levels and their correlation to disease relapse and survival in
endometrial cancer. Arch Gynecol Obstet. 292:647–654. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sun Z and Zhang N: Clinical evaluation of
CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with
neoadjuvant chemotherapy. World J Surg Oncol. 12:3972014.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Katz MH, Varadhachary GR, Fleming JB,
Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang
H, et al: Serum CA 19-9 as a marker of resectability and survival
in patients with potentially resectable pancreatic cancer treated
with neoadjuvant chemoradiation. Ann Surg Oncol. 17:1794–1801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Škrha P, Hořínek A, Anděl M and Škrha J:
miRNA-192, miRNA-21 and miRNA-200: New pancreatic cancer markers in
diabetic patients? Vnitr Lek. 61:351–354. 2015.In Czech.
|
|
76
|
Körner M, Waser B, Strobel O, Büchler M
and Reubi JC: Neurotensin receptors in pancreatic ductal
carcinomas. EJNMMI Res. 5:172015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang J, Zuo CJ, Jia NY, Wang JH, Hu SP,
Yu ZF, Zheng Y, Zhang AY and Feng XY: Cross-modality PET/CT and
contrast-enhanced CT imaging for pancreatic cancer. World J
Gastroenterol. 21:2988–2996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Okano K, Oshima M, Yamamoto N and Suzuki
Y: PET imaging in the diagnosis of pancreatic cancer. Nihon Rinsho.
73(Suppl 3): 79–83. 2015.In Japanese.
|
|
79
|
Wang Z and Tian YP: Clinical value of
serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of
pancreatic carcinoma. Mol Clin Oncol. 2:265–268. 2014.PubMed/NCBI
|
|
80
|
Yang Y, Chen H, Wang D, Luo W, Zhu B and
Zhang Z: Diagnosis of pancreatic carcinoma based on combined
measurement of multiple serum tumor markers using artificial neural
network analysis. Chin Med J (Engl). 127:1891–1896. 2014.
|
|
81
|
Nolen BM, Brand RE, Prosser D,
Velikokhatnaya L, Allen PJ, Zeh HJ, Grizzle WE, Huang Y, Lomakin A
and Lokshin AE: Prediagnostic serum biomarkers as early detection
tools for pancreatic cancer in a large prospective cohort study.
PLoS One. 9:e949282014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Chang ST, Zahn JM, Horecka J, Kunz PL,
Ford JM, Fisher GA, Le QT, Chang DT, Ji H and Koong AC:
Identification of a biomarker panel using a multiplex proximity
ligation assay improves accuracy of pancreatic cancer diagnosis. J
Transl Med. 7:1052009. View Article : Google Scholar : PubMed/NCBI
|
